Article Text

PDF
Statins: a new approach to combat temozolomide chemoresistance in glioblastoma
  1. Shahla Shojaei1,2,
  2. Javad Alizadeh1,
  3. James Thliveris1,
  4. Navid Koleini3,4,
  5. Elissavet Kardami1,3,4,
  6. Grant M Hatch5,
  7. Fred Xu5,
  8. Sabine Hombach-Klonisch1,
  9. Thomas Klonisch1,
  10. Saeid Ghavami1,6,7
  1. 1 Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
  2. 2 Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3 Physiology and Pathophysiology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
  4. 4 Institute of Cardiovascular Sciences, St. Boniface Hospital AlbrechtsenResearch Center, Winnipeg, Manitoba, Canada
  5. 5 Pharmacology & Therapeutics, Max Rady College of Medicine, Rady Faculty of Helath Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
  6. 6 Biology of Breathing Theme, Children Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada
  7. 7 Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Fars, Iran
  1. Correspondence to Dr Saeid Ghavami, Department of Human Anatomy and Cell Sciences, Winnipeg R3E0J9, Canada; saeid.ghavami{at}umanitoba.ca

Abstract

Patients with glioblastoma multiforme (GBM) have an average life expectancy of approximately 15 months. Recently, statins have emerged as a potential adjuvant cancer therapy due to their ability to inhibit cell proliferation and induce apoptosis in many types of cancer. The exact mechanisms that mediate the inhibitory actions of statins in cancer cells are largely unknown. The purpose of this proceeding paper is to discuss some of the known anticancer effects of statins, while focusing on GBM therapy that includes adjunct therapy of statins with chemotherapeutic agents.

  • brain diseases
  • cell death
  • cholesterol
  • cancer

Statistics from Altmetric.com

Footnotes

  • Contributors All co-authors have particiapted in prepration of the proceedings and have read and proved the manuscript.

  • Funding SG and SS were supported by a Health Science Centre General Operating grant and Research Manitoba New Investigator Award. SS was also supported by a Mitacs Accelerate postdoctoral fellowship. SHK and TK are supported by the Natural Sciences and Engineering Council of Canada (NSERC) and the Cancer Research Society (CRS). GH: Heart and Stroke Foundation of Canada and holds the Canada Research Chair in Molecular Cardiolipin Metabolism.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

  • Presented at Experimental Biology Conference, San Diego Convention Centre, April 21 to 25, 2018. Symposium: The Mevalonate Pathway: A fundamental Player In Human Disease, Saturday, April 21 2018. Sponsored by: American Federation for Medical Research (AFMR). Presentation: Mevalonate pathway regulation of cell fate: autophagy, apoptosis, and ER stress. By Dr Saeid Ghavami, University of Manitoba.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.